Etanercept is effective in Juvenile Idiopathic Arthritis (JIA).[1-3] Currently it is administered subcutaneously (SC) in the dose of 0,4 mg/kg (maximum of 25 mg) twice weekly. Clinical trials in adults show that the administering of an once weekly double dose is effective enough to induce and retain remission.[4, 5] A farmakinetic model developed by Yim et al. indicates that the same dosing regime could be used in children.  Wallace mentions the once weekly double dose in patients with JIA, but this is not supported by clinical trials. Therefore we evaluated the efficacy of etanercept administered once weekly in the dose of 0,8 mg/kg SC (maximum of 50 mg) to retain and induce remission in patients with JIA.
- Juvenile Idiopathic Arthritis
- double dose
- once weekly